Vimarsana
Biggest News Aggregation in the World

Clinical Development Centers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Development Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Development Centers Today - Breaking & Trending Today

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024 - Vimarsana News

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

Published: May 24, 2024

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities...

Source: prnewswire.com
Related Topics:
United StatesLos AngelesProduct Development CenterPrnewswire Transcenta Holding LimitedTranscenta Immune Tolerance Breaking TechnologyClinical Development Centers In PrincetonGroup HeadquartersTranslational Research CenterHolding LimitedClinical Oncology VolumeImmune Tolerance Breaking TechnologyOrphan Drug DesignationManufacturing FacilityClinical Development CentersExternal Partnering CenterSuzhou Industrial
Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023 - Vimarsana News

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

Published: October 23, 2023

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all

Source: thailand-business-news.com
Related Topics:
United StatesCaroline GermaLos AngelesTranscenta HoldingTranscenta Immune Tolerance Breaking TechnologyTranscenta Holding LimitedClinical Development Centers In PrincetonTranslational Research CenterProduct Development CenterGlobal Medicine DevelopmentGroup HeadquartersExecutive Vice PresidentChief MedicalManageable SafetyImmune Tolerance Breaking TechnologyOrphan Drug DesignationManufacturing FacilityClinical Development CentersExternal Partnering CenterSuzhou Industrial
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients - Vimarsana News

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

Published: October 4, 2023

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

Source: prnewswire.com
Related Topics:
South KoreaUnited StatesLos AngelesCaroline GermaProduct Development CenterTranscenta HoldingPrnewswire Transcenta Holding LimitedBusiness Development CenterClinical Development Centers In PrincetonGroup HeadquartersGlobal Medicine DevelopmentTranslational Research CenterTranscenta Immune Tolerance Breaking TechnologyGlobal TherapyCurrent StandardHolding LimitedDrug EvaluationTranscenta Executive Vice PresidentChief MedicalCancer StatisticsMortality WorldwideGastric Cancer VersionImmune Tolerance Breaking TechnologyOrphan Drug DesignationManufacturing Facility
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density - Vimarsana News

Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density

Published: July 31, 2023

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

Source: prnewswire.com
Related Topics:
United StatesEvenity RomosozumabLos AngelesTranscenta HoldingChina CenterGlobal Medicine DevelopmentPrnewswire Transcenta Holding LimitedGroup HeadquartersTranslational Research CenterProduct Development CenterClinical Development Centers In PrincetonHolding LimitedDrug EvaluationExecutive Vice PresidentChief MedicalManufacturing FacilityClinical Development CentersExternal Partnering CenterSuzhou IndustrialTranscenta Holding Limited
Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001) - Vimarsana News

Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)

Published: July 7, 2023

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

Source: prnewswire.com
Related Topics:
South KoreaUnited StatesCaroline GermaLos AngelesGlobal Medicine DevelopmentTranscenta Immune Tolerance Breaking TechnologyTranscenta HoldingClinical Development Centers In PrincetonGroup HeadquartersProduct Development CenterPrnewswire Transcenta Holding LimitedTranslational Research CenterMinistry Of FoodBusiness Development CenterHolding LimitedDrug EvaluationDrug SafetyExecutive Vice PresidentChief MedicalImmune Tolerance Breaking TechnologyOrphan Drug DesignationManufacturing FacilityClinical Development CentersSuzhou IndustrialTranscenta Holding Limited